Loxo Oncology Inc (LOXO) CEO Sells $1,448,550.00 in Stock

Loxo Oncology Inc (NASDAQ:LOXO) CEO Joshua H. Bilenker sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $96.57, for a total value of $1,448,550.00. Following the completion of the sale, the chief executive officer now directly owns 190,207 shares of the company’s stock, valued at approximately $18,368,289.99. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Loxo Oncology Inc (NASDAQ:LOXO) traded up $3.43 during mid-day trading on Wednesday, hitting $104.35. The stock had a trading volume of 504,068 shares, compared to its average volume of 344,973. Loxo Oncology Inc has a 52 week low of $40.01 and a 52 week high of $108.50. The company has a market capitalization of $2,812.33, a price-to-earnings ratio of -17.31 and a beta of 2.57.

A number of brokerages have commented on LOXO. BidaskClub raised Loxo Oncology from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Zacks Investment Research raised Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. William Blair began coverage on Loxo Oncology in a research note on Tuesday, November 28th. They issued an “outperform” rating for the company. Citigroup reduced their price objective on Loxo Oncology from $112.00 to $108.00 and set a “buy” rating for the company in a research note on Thursday, November 16th. Finally, JMP Securities upgraded Loxo Oncology from a “market perform” rating to an “outperform” rating and raised their target price for the company from $77.18 to $95.00 in a report on Tuesday, November 14th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $97.33.

Several hedge funds have recently bought and sold shares of LOXO. Wells Fargo & Company MN lifted its holdings in Loxo Oncology by 3.8% during the second quarter. Wells Fargo & Company MN now owns 16,095 shares of the biopharmaceutical company’s stock worth $1,291,000 after acquiring an additional 592 shares during the period. Teachers Advisors LLC lifted its holdings in Loxo Oncology by 29.6% during the second quarter. Teachers Advisors LLC now owns 36,502 shares of the biopharmaceutical company’s stock worth $2,927,000 after acquiring an additional 8,340 shares during the period. TIAA CREF Investment Management LLC lifted its holdings in Loxo Oncology by 34.9% during the second quarter. TIAA CREF Investment Management LLC now owns 54,986 shares of the biopharmaceutical company’s stock worth $4,409,000 after acquiring an additional 14,214 shares during the period. BlackRock Inc. lifted its holdings in Loxo Oncology by 20.6% during the second quarter. BlackRock Inc. now owns 1,602,885 shares of the biopharmaceutical company’s stock worth $128,534,000 after acquiring an additional 273,291 shares during the period. Finally, New York State Common Retirement Fund lifted its holdings in Loxo Oncology by 55.4% during the second quarter. New York State Common Retirement Fund now owns 24,397 shares of the biopharmaceutical company’s stock worth $1,956,000 after acquiring an additional 8,696 shares during the period.

COPYRIGHT VIOLATION WARNING: “Loxo Oncology Inc (LOXO) CEO Sells $1,448,550.00 in Stock” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2018/02/14/loxo-oncology-inc-loxo-ceo-sells-1448550-00-in-stock.html.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply